top of page
  • Active, not recruiting

NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420

Updated: Sep 2, 2022

AMG 420


AMG420

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.


Sponsor


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03836053


Official Title: A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma

First Posted : February 11, 2019


Click here for details on ClinicalTrials.gov

 
 

Pacanalotamab

AMG 420

BI 836909

 

- New York: Memorial Sloan-Kettering Cancer Center New York

- Massachusetts: Massachusetts General Hospital Boston

- North Carolina: Wake Forest Baptist Health Winston-Salem

 

Locations

United States, Illinois

United States, Massachusetts

United States, New York

United States, North Carolina

Australia, New South Wales

Australia, Victoria

Europe

Belgium

Switzerland

Asia

Japan





Comments


Posts Archive
bottom of page